Add 2 More Reports For 20% off

Report Overview

The global Gemcitabine HCl market reached a value of USD 719.26 million in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 7.4% during the forecast period of 2024-2032 to achieve a value of USD 1,367.49 million by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

“Gemcitabine HCL Market Report and Forecast 2024-2032” offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

  • Branded
  • Generics

Market Breakup by Indications

  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Biliary Tract Cancer
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

This increase in the number of cancer cases, along with the rising geriatric population and the associated risk factors, is driving the industry for gemcitabine HCL. Further, with the rise in the number of governmental and healthcare patient support organisations and agencies, which are spreading awareness regarding cancer, the industry is expected to receive a further boost. Technical advancements in the production of generic drugs have led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market over the forecast period.

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

The report presents a detailed analysis of the following key players in the global gemcitabine HCL market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Eli Lilly and Company (NYSE: LLY)
  • Teva Pharmaceutical Industries Ltd.  
  • Accord Healthcare Ltd. 
  • Pfizer, Inc. 
  • Mylan N.V. 
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG 
  • Dr. Reddy’s Laboratories Ltd. 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global market for gemcitabine HCL reached a value of over USD 719.26 million in 2023.

Over the forecast period of 2024-2032, the market is anticipated to grow at a CAGR of 7.4% to reach USD 1,367.49 million by 2032.

The major drivers of the industry, such as the growing prevalence of cancer and other diseases, rising disposable incomes, increasing population, growing demand for generic drugs, increased government initiatives to create health awareness, growing geriatric population, and rapid advancement in the field of medicine and science, are expected to aid the market growth.

The key market trends guiding the growth of the market include the growing investment in the research and development of drugs and growth in the number of clinical trials being conducted across the globe.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Branded and generic are the major gemcitabine HCL types in the industry.

The significant applications of the product are pancreatic cancer, breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC), among others.

Hospitals and cancer centres, among others, are the major end use sectors of the product.

The major players in the industry are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, and Dr. Reddy’s Laboratories Ltd., among others.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Indications
  • End User
  • Distribution Channel
  • Region
Breakup by Type
  • Branded
  • Generics
Breakup by Indications
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Biliary Tract Cancer
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Centers
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • HEYER Medical AG
  • Biometrix
  • Smith’s Medical
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124